Options
綠膿桿菌二氫嘧啶水解酵素結晶結構之解析
Date Issued
2016
Author(s)
黃建智
Chien-Chih Huang
Advisor
黃晟洋
Abstract
二氫嘧啶水解酵素 (dihydropyrimidinase) 是一個含有後修飾羧化賴氨酸(post-carboxylated lysine) 的雙金屬酵素,可催化dihydrouracil與dihydrothymine變成N-carbamoyl-β-alanine與N-carbamyl-β-aminoisobutyrate,是DNA 鹼基代謝途徑中極重要的酵素,並廣泛存在於各生物間。除了來自於假單胞菌屬(Pseudomonas) 的二氫嘧啶水解酵素是雙套體外,目前已知所有的此酵素皆為四套體。在此研究,我們將來自綠膿桿菌 (Pseudomonas aeruginosa) 的二氫嘧啶水解酵素基因選殖、大量表達於大腸桿菌、純化與結晶、利用分子置換法解出其結晶結構,並上傳至蛋白質結構資料庫 (Protein Data Bank; PDB)。在我們進行初步結晶條件篩選時,發現有兩種主要結晶條件可得到此酵素晶體,分別為10% PEG 8000、100 mM HEPES、200 mM calcium acetate、pH 5.9與28% PEG 6000、100 mM HEPES、200 mM lithium acetate、pH 7.5。然令人意外的是,此兩種晶體除所屬的空間群 (space group) 不同外,其所解出的結構亦分別有四套體 (tetramer) 與雙套體 (dimer) 兩種 (蛋白質結構序號分別為5E5C與5IWV),引發了我們對此酵素在溶液中是否亦形成有不同的寡聚體狀態 (oligomerization state) 的研究興趣。我們利用膠體過濾層析分析法 (gel filtration) 發現此酵素在不同的酸鹼度下確實存在著不同四級結構的型態,分別為單套體、雙套體與四套體三種。我們比較此兩個不同型態的結晶結構,並根據結構說明了為何假單胞菌屬的二氫嘧啶水解酵素為雙套體而非廣泛認知的四套體。另外,由於在先前的研究中已發現此酵素可能為一好的新型抗生素標靶,我們亦利用此結晶結構與分子對接 (molecular docking) 方式來說明抑制劑如dihydromyricetin對此酵素的分子抑制機制,並希望試圖據此結構進行下一階段的藥物設計優化、建議出更多的潛在候選抗生素藥物供臨床試驗。
Dihydropyrimidinase, a dimetalloenzyme containing a post-carboxylated lysine within the active site, catalyzes the reversible cyclization of dihydrouracil or dihydrothymine to N-carbamoyl-β-alanine or N-carbamyl-β-aminoisobutyrate in the second step of the pyrimidine degradation pathway, respectively. All known dihydropyrimidinases are tetrameric; however, Pseudomonal dihydropyrimidinase forms a dimer. In this study, Pseudomonas aeruginosa dihydropyrimidinase was cloned, expressed, purified, and crystallized, and the crystal structures (PDB ID: 5E5C and 5IWV) were determined. At the initial screening, two different crystallization conditions were found: (1) 10% PEG 8000, 100 mM HEPES, 200 mM calcium acetate at pH 5.9; (2) 28% PEG 6000, 100 mM HEPES, 200 mM lithium acetate at pH 7.5. However, these two crystals belonged to different space groups, and the resolved structures had two forms, namely, a tetramer and a dimer. The gel filtration chromatographic analysis indicated that this enzyme formed a mixture of a monomer, a dimer, and a tetramer, and the oligomerization states were pH dependent. Based on these results, we discussed why Pseudomonas aeruginosa dihydropyrimidinase form a dimer, not a tetramer. In addition, given that microbial dihydropyrimidinase is a new drug target, the binding mode of dihydromyricetin, a potent inhibitor of dihydropyrimidinase, was also studied by the molecular docking and these crystal structures for antibiotics development. We hope that more inhibitors of this enzyme can be found as drug candidates for clinical use.
Subjects
綠膿桿菌
二氫嘧啶水解酵素
Pseudomonas aeruginosa
dihydropyrimidinase
Type
thesis
File(s)
No Thumbnail Available
Name
104CSMU5114020-001.zip
Size
2.68 MB
Format
Unknown
Checksum
(MD5):b9f0068b3d886f8bde7de26aff230498